首页> 外国专利> CRISPR-BASED FOXP3 GENE ENGINEERED T CELLS AND HEMATOPOIETIC STEM CELL PRECURSORS TO TREAT IPEX SYNDROME PATIENTS

CRISPR-BASED FOXP3 GENE ENGINEERED T CELLS AND HEMATOPOIETIC STEM CELL PRECURSORS TO TREAT IPEX SYNDROME PATIENTS

机译:基于CRISPR的FOXP3基因工程T细胞和造血干细胞前体治疗IPEX综合征患者

摘要

Compositions and methods are provided relating to FOXP3 gene edited hematopoietic cells, include hematopoietic stem and progenitor cells, lymphoid progenitor cells, and CD4+ T cells. The gene edited cells are useful in cellular therapy to restore normal immune functions and promote immune tolerance. In particular, CD4edFOXP3 T cells, which may be differentiated from FOXP3 gene edited hematopoietic progenitor cells, can physiologically express functional FOXP3 and exert normal immune responses as effector T cells or have immune suppressive characteristics as naturally occurring Treg cells.
机译:提供了与Foxp3基因编辑造血细胞有关的组合物和方法,包括造血干细胞和祖细胞,淋巴祖细胞和CD4 + T细胞。 基因编辑细胞可用于细胞疗法以恢复正常免疫功能并促进免疫耐受性。 特别地,可以从FoxP3基因被编辑的造血祖细胞分化的CD4 EDFOXP3 T细胞可以生理学上表达功能性FOXP3并将正常的免疫应答作为效应T细胞施加,或者具有自然发生的免疫抑制特征或具有自然的Treg 细胞。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号